Celgene International Sárl (CELG) Release: Final Data from Phase II Multi-Center Study Evaluating Combination of VIDAZA® and REVLIMID® in Higher-Risk MDS Patients Presented at American Society of Hematology
12/13/2011 6:50:59 AM
BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG), today reported final results from the phase II portion of a multi-center phase I/II study evaluating combination therapy with REVLIMID (lenalidomide) and VIDAZA (azacitidine) in patients with higher-risk myelodysplastic syndromes (MDS) not previously treated with either drug. These data were presented at the 53rd Annual Meeting of the American Society of Hematology in San Diego, CA.
comments powered by